106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies, at GuidelineCentral.com
Copyright © 2017 All rights reserved
ESPEDOB1733
Disclaimer
is Guideline attempts to define principles of practice that should produce high-quality
patient care. It focuses on the needs of primary care practice, but also is applicable to providers
at all levels. is Guideline should not be considered exclusive of other methods of care
reasonably directed at obtaining the same results. e ultimate judgment concerning the
propriety of any course of conduct must be made by the clinician aer consideration of each
individual patient situation.
Neither IGC, the medical associations, nor the authors endorse any product or service
associated with the distributor of this clinical reference tool.
Source
Styne DM, Arslanian SA, Connor EL, Farooqi IS, Murad MH, Silverstein JH, Yanovski
JA. Pediatric Obesity—Assessment, Treatment, and Prevention: An Endocrine Society
Clinical Practice Guideline. J Clin Endocrinol Metab. March 2017, 102(3):1–49.
Abbreviations
ACTH, adrenocorticotropic hormone; AOR, adjusted odds ratio; BMI, body mass index;
BDNF, brain-derived neurotrophic factor; BP, blood pressure; CI, confidence interval;
CNS, central nervous system; DNA, Deoxyribonucleic Acid; ES, Endocrine Society; FT4,
(plasma) free thyroxine; GH, growth hormone; HDL, high-density lipoprotein; HR,
heart rate; HTN, hypertension; IFG, impaired fasting glucose; IGT, impaired glucose
tolerance; IQR, interquartile range; IV, intravenous; LAGB, laparoscopic adjustable
gastric banding ; LDL, low-density lipoprotein; MAOI, monoamine oxidase inhibitor;
MVI, multivitamins; NAFLD, non-alcoholic fatty liver disease; OGTT, oral glucose
tolerance test (1.75 g/kg, maximum 75 g ); PCOS, polycystic ovary syndrome; POMC,
proopiomelanocortin; RCT, randomized controlled trial; RYGB, Roux-en-Y gastric
bypass; SBP, systolic blood pressure; SKOT, Scottish Childhood Obesity Treatment
Trial; SMD, standardized mean difference; SNRI, selective serotonin-norepinephrine
reuptake inhibitors; SSRI, selective serotonin-reuptake inhibitors; T2DM, type 2 diabetes
mellitus; TV, television; HDL, high-density lipoprotein; T4, thyroxine; TG, triglyceride;
VO
2
, oxygen consumption; VSG, vertical sleeve gastrectomy
Grading System
Strength of
Recommendation
1 = strong 2 = weak U = ungraded
Quality of
Evidence
⊕⊕⊕⊕
= high
⊕⊕⊕
= moderate
⊕⊕
= low
⊕
= very low
